NEW EVENT! Formulation Advancements in the Treatment of mCRPC ~ Join us January 14th, 2025Social Media CoordinatorDec 27, 20240 min readREGISTERPM-US-YON-0708 Yonsa Speaker Program Learning Objective Digital Sheet (1).pdfDownload PDF • 613KB
CAR-Therapy Adverse Reaction Identification and Management Considerations ~ Thursday, June 12th @ Davio's
NEW EVENT: Exploring the Role of NUBEQA (darolutamide) in mHSPC in Combination with Docetaxel and in nmCRPC PP-NUM-US-3389-1
Comentários